DEFA14A: Quipt Home Medical to be Acquired for $260M Cash

Quipt Home Medical Corp. will be acquired by affiliates of Kingswood Capital Management and Forager Capital Management for US$3.65 per share in an all-cash transaction.

Summary

• Quipt Home Medical Corp. has entered into an Arrangement Agreement to be acquired by 1567208 B.C. LTD and REM Aggregator, LLC, entities affiliated with Kingswood Capital Management, LP and Forager Capital Management, LLC.
• The acquisition price is US$3.65 per common share in cash.
• The transaction values Quipt at approximately US$260 million, including existing outstanding debt.
• The per-share purchase price represents a 162% premium to Quipt's unaffected stock price on May 19, 2025, and a 54% premium to its 30-day VWAP as of December 12, 2025.
• Quipt's Board of Directors unanimously approved the Arrangement, deeming the consideration fair and in the best interests of the Company, and recommends shareholders vote in favor.
• The transaction is not subject to any financing condition, with Kingswood providing an equity commitment letter.
• Upon completion, Quipt's shares will be delisted from The Nasdaq Capital Market and the Toronto Stock Exchange, and the company will cease to be a Canadian reporting issuer and de-registered under the Securities Exchange Act of 1934.
• Outstanding Company Options and Restricted Share Units (RSUs) will vest and be exchanged for cash payments based on the US$3.65 per share price, less exercise price for options (options with exercise price >= $3.65 will be cancelled for no consideration).
• Directors and executive officers, along with Forager Fund, L.P., holding approximately 20.9% of outstanding shares, have entered into voting and support agreements to vote in favor of the transaction.

Sentiment

Score: 9

Explanation: The sentiment is highly positive for existing shareholders due to the significant premium offered, the all-cash nature of the deal providing certainty and liquidity, and the unanimous board recommendation. The transaction is not subject to financing conditions, further de-risking the deal for shareholders.

Positives

• Shareholders receive a significant premium: 162% over the unaffected stock price on May 19, 2025, and 54% over the 30-day VWAP as of December 12, 2025.
• The all-cash transaction provides immediate liquidity and certainty of value for Quipt shareholders.
• The transaction is not subject to a financing condition, reducing execution risk.
• The Board of Directors unanimously approved the deal and recommends it to shareholders, indicating strong internal support.

Negatives

• Quipt shares will be delisted from major exchanges (Nasdaq and TSX), removing public trading access.
• The company will cease to be a reporting issuer, reducing transparency and public disclosure.
• Shareholders will no longer participate in any potential future growth or upside of Quipt as a private entity.
• Options with an exercise price equal to or greater than US$3.65 will be cancelled for no consideration, potentially disadvantaging some option holders.

Risks

• Failure to obtain the required shareholder approval (66% of votes cast, and potentially a simple majority excluding certain votes under MI 61-101).
• Failure to obtain necessary court approvals (Interim and Final Order).
• Failure to receive HSR Act approval or expiration of the waiting period.
• Enactment of any law making the Arrangement illegal or prohibiting its consummation.
• Exercise of dissent rights by more than 10% of issued and outstanding shares could prevent the transaction.
• Occurrence of a Material Adverse Effect on Quipt prior to closing.
• Breach of representations, warranties, or covenants by either party could lead to termination of the agreement.
• Significant transaction costs, unknown liabilities, and the risk of litigation and/or regulatory actions related to the proposed transaction.

Future Outlook

The transaction is expected to close in the first half of 2026, subject to customary closing conditions including shareholder, regulatory, and court approvals. Following completion, Quipt will become a privately held company, delisted from public exchanges, and will cease to be a reporting issuer. The acquirers, Kingswood and Forager, intend to partner with Quipt's management to support the company's next chapter of growth, reignite the M&A engine to expand in strategic markets, and continue investing in people, technology, and clinical care.

Management Comments

• Greg Crawford, Chairman and CEO of Quipt, stated, 'The Board has consistently demonstrated its commitment to maximizing shareholder value, and we believe this transaction achieves that objective by providing substantial and assured value to our shareholders.'
• Crawford also extended gratitude to the Quipt team, noting their dedication, compassion, and drive as fundamental to accomplishments, and expressed optimism for Quipt's established legacy of outstanding in-home respiratory care to achieve even greater growth.
• Kingswood Partner Michael Niegsch and Forager Partner Johnny Wilhelm jointly commented, 'Quipt has built a a high quality, scaled respiratory care platform defined by its patient-centric care model, durable referral relationships, and attractive recurring revenue base.'
• Niegsch and Wilhelm added, 'We are excited to partner with Greg Crawford, Hardik Mehta, and the entire Quipt team to support the Company's next chapter of growth as a privately held company. We look forward to reigniting the M&A engine to expand in strategic markets, while continuing to invest in people, technology, and best-in-class clinical care.'

Industry Context

This acquisition reflects a trend of private equity firms (Kingswood Capital Management) and investment funds (Forager Capital Management) seeking to acquire established companies in specialized healthcare sectors like home medical equipment and respiratory care. The focus on 'patient-centric care model, durable referral relationships, and attractive recurring revenue base' highlights the value drivers in this industry, particularly for companies with a strong operational foundation. The intent to 'reignite the M&A engine' suggests a strategy to consolidate and expand within the fragmented home healthcare market, leveraging private capital for growth that might be more challenging or slower in the public market.

Comparison to Industry Standards

• The 162% premium to Quipt's unaffected stock price and 54% premium to its 30-day VWAP are significantly above average for public company acquisitions, indicating a strong valuation for Quipt within its sector.
• The acquisition by private equity (Kingswood) and an investment fund (Forager) is consistent with broader industry trends where private capital seeks to acquire and grow companies in stable, recurring-revenue healthcare services, often with a view to optimize operations and pursue further M&A away from public market scrutiny.

Corporate Governance

Legal Proceedings

• The company will oppose and seek to lift or rescind any injunction, restraining or other order, decree or ruling seeking to restrain, enjoin or otherwise prohibit or adversely affect the consummation of the Arrangement.
• The company will defend any proceedings to which it or any of its subsidiaries is a party or brought against it or any of their directors or officers challenging the Arrangement or the Arrangement Agreement.

Related Party Transactions

• Forager Fund, L.P., an entity affiliated with one of the purchasers (Forager Capital Management, LLC), has entered into a voting and support agreement to vote its approximately 9.5% stake in favor of the transaction.
• Directors and executive officers of Quipt, including Gregory Crawford and Hardik Mehta, who collectively hold approximately 11.4% of outstanding shares, have entered into voting and support agreements to vote in favor of the transaction.

Stakeholder Impact

• **Shareholders**: Will receive US$3.65 per share in cash, representing a significant premium and providing immediate liquidity and certainty of value. They will no longer hold shares in a publicly traded company.
• **Employees**: Management comments express gratitude to the Quipt team and anticipate 'even greater growth in the future' under new ownership, suggesting continued employment and potential for expansion.
• **Management**: Key executives (Greg Crawford, Hardik Mehta) are expected to partner with the acquirers for the company's next growth phase, indicating continuity in leadership.
• **Customers/Patients**: The acquirers emphasize Quipt's 'patient-centric care model' and 'best-in-class clinical care,' suggesting a continued focus on service quality and potential expansion of offerings.

Next Steps

• Quipt will apply to the Court for an Interim Order to call and hold a special meeting of shareholders.
• Quipt will prepare and file a management information circular and proxy statement (Circular) with the SEC and Canadian securities regulatory authorities.
• Quipt will mail the Circular to shareholders to solicit votes for the Arrangement Resolution.
• A special meeting of Quipt shareholders will be held to vote on the Arrangement Resolution, requiring approval from 66% of votes cast and potentially a simple majority excluding certain votes.
• If shareholder approval is obtained, Quipt will apply to the Court for a Final Order to approve the Arrangement.
• The transaction is expected to close in the first half of 2026.
• Upon closing, Quipt shares will be delisted from Nasdaq and TSX, and the company will cease to be a reporting issuer.

Key Dates

Recommendation

The acquisition offers a substantial premium of 162% over the unaffected stock price and 54% over the 30-day VWAP, providing a clear and attractive exit for current shareholders. The all-cash nature of the deal, coupled with unanimous board approval and no financing condition, significantly de-risks the transaction. For a seasoned investor, selling now or holding for the arbitrage spread to capture this premium offers a certain return, especially given the impending delisting and loss of public market access.

Keywords

Quipt Home Medical, Acquisition, Kingswood Capital Management, Forager Capital Management, Merger, Healthcare, Home Medical Equipment, Respiratory Care, SEC Filing, QIPT, Plan of Arrangement, Delisting